Jiangxi Synergy Pharmaceutical Co Ltd (300636) - Total Assets
Based on the latest financial reports, Jiangxi Synergy Pharmaceutical Co Ltd (300636) holds total assets worth CN¥3.31 Billion CNY (≈ $484.59 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Jiangxi Synergy Pharmaceutical Co Ltd debt service capacity to assess how comfortably operating cash covers total debt obligations.
Jiangxi Synergy Pharmaceutical Co Ltd - Total Assets Trend (2012–2025)
This chart illustrates how Jiangxi Synergy Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Jiangxi Synergy Pharmaceutical Co Ltd for net asset value and shareholders' equity analysis.
Jiangxi Synergy Pharmaceutical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Jiangxi Synergy Pharmaceutical Co Ltd's total assets of CN¥3.31 Billion consist of 44.0% current assets and 56.0% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.6% |
| Accounts Receivable | CN¥117.83 Million | 3.6% |
| Inventory | CN¥510.45 Million | 15.4% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥18.75 Million | 0.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Jiangxi Synergy Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Jiangxi Synergy Pharmaceutical Co Ltd.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Jiangxi Synergy Pharmaceutical Co Ltd's current assets represent 44.0% of total assets in 2025, an increase from 41.8% in 2012.
- Cash Position: Cash and equivalents constituted 7.6% of total assets in 2025, up from 4.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 15.4% of total assets.
Jiangxi Synergy Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Jiangxi Synergy Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
|
China | CN¥12.75 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.84 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.69 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211
|
China | CN¥6.39 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
Jiangxi Synergy Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.82 | 1.98 | 2.16 |
| Quick Ratio | 1.15 | 1.03 | 0.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥645.88 Million | CN¥576.48 Million | CN¥331.28 Million |
Jiangxi Synergy Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Jiangxi Synergy Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.18 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 0.0% |
| Total Assets | CN¥3.32 Billion |
| Market Capitalization | $412.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values Jiangxi Synergy Pharmaceutical Co Ltd's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Jiangxi Synergy Pharmaceutical Co Ltd's assets decreased by 0.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Jiangxi Synergy Pharmaceutical Co Ltd (2012–2025)
The table below shows the annual total assets of Jiangxi Synergy Pharmaceutical Co Ltd from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.32 Billion ≈ $485.97 Million |
+0.04% |
| 2024-12-31 | CN¥3.32 Billion ≈ $485.75 Million |
+3.05% |
| 2023-12-31 | CN¥3.22 Billion ≈ $471.40 Million |
+42.61% |
| 2022-12-31 | CN¥2.26 Billion ≈ $330.54 Million |
+18.47% |
| 2021-12-31 | CN¥1.91 Billion ≈ $279.01 Million |
+29.92% |
| 2020-12-31 | CN¥1.47 Billion ≈ $214.77 Million |
+44.50% |
| 2019-12-31 | CN¥1.02 Billion ≈ $148.63 Million |
+26.39% |
| 2018-12-31 | CN¥803.62 Million ≈ $117.59 Million |
+11.26% |
| 2017-12-31 | CN¥722.28 Million ≈ $105.69 Million |
+72.40% |
| 2016-12-31 | CN¥418.96 Million ≈ $61.31 Million |
+20.17% |
| 2015-12-31 | CN¥348.64 Million ≈ $51.02 Million |
+35.50% |
| 2014-12-31 | CN¥257.30 Million ≈ $37.65 Million |
+9.29% |
| 2013-12-31 | CN¥235.43 Million ≈ $34.45 Million |
+24.68% |
| 2012-12-31 | CN¥188.82 Million ≈ $27.63 Million |
-- |
About Jiangxi Synergy Pharmaceutical Co Ltd
Jiangxi Synergy Pharmaceutical Co., Ltd. engages in research and development, production, and sales of chemical raw materials and pharmaceutical intermediates in China and internationally. The company offers nervous system drugs, digestive system medications, antipyretic analgesics and non-steroidal anti-inflammatory analgesics, antihypertensive drugs, anticoagulants, hypoglycemic drugs, antidepr… Read more